A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells. The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors. For this, the researchers will study and analyze: * the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity. * the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose. * the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses. * the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses. Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse. The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase. Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems. Participants will visit the study site: * at least twice before the treatment starts * multiple times when they start taking the treatment * once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason During the study, the doctors and their study team will: * check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram * check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan * take tumor samples The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek minimum 18 lat
- •Co najmniej jeden mierzalny guzek, który można obserwować w badaniach obrazowych
- •Potwierdzona delecja genu MTAP wykazana w badaniu genetycznym
- •Ogólny stan zdrowia pozwalający na aktywność codzienną (ECOG 0 lub 1)
✗ Disqualifies
- •Inny nowotwór w ciągu ostatnich 2 lat (poza nowotworami skóry lub raka szyjki macicy)
- •Poważne zaburzenia rytmu serca (przedłużony interval QT/QTc)
- •Historia zawału serca w ciągu ostatnich 6 miesięcy
- •Niestabilna choroba niedokrwienna serca w ciągu ostatnich 4 tygodni
- •Historia poważnej niewydolności serca
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (63)
UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
Birmingham, United States
City of Hope - Duarte Cancer Center
Duarte, United States
UCLA Health Bowyer Oncology Center
Los Angeles, United States
UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
San Francisco, United States
Stanford University Medical Center - Neurology
Stanford, United States
UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
Aurora, United States
Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
Denver, United States
Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona
Orlando, United States
Massachusetts General Hospital - Neurology
Boston, United States
Dana-Farber Cancer Institute - Oncology Department
Boston, United States
START | Midwest
Grand Rapids, United States
Icahn School of Medicine at Mount Sinai - Oncology
New York, United States
Memorial Sloan Kettering Cancer Center New York - Main Campus
New York, United States
SCRI Oncology Partners
Nashville, United States
NEXT Dallas - Oncology Department
Irving, United States
START | San Antonio
San Antonio, United States
Froedtert Hospital - Clinical Cancer Center
Milwaukee, United States
Chris O'Brien Lifehouse
Camperdown, Australia
Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre
Concord, Australia
Northern Hospital
Epping, Australia
Calvary Mater Hospital Newcastle - Oncology
Waratah, Australia
Antwerp University Hospital | Oncology Department
Antwerp, Belgium
Ghent University Hospital | Drug Research Unit Department
Ghent, Belgium
UZ Leuven Gasthuisberg - Pneumology Department
Leuven, Belgium
Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology
Liège, Belgium
Beijing Cancer Hospital - Oncology Department
Beijing, China
Beijing chest hospital, Capital Medical University
Beijing, China
Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
Wuhan, China
Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
Hangzhou, China
Fakultní nemocnice Olomouc - Onkologická klinika
Olomouc, Czechia
Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)
Brno, Czechia
Rigshospitalet Copenhagen University Hospital | Oncology Department
Copenhagen, Denmark
Odense University Hospital | Svendborg Sygehus - Oncology Department
Odense, Denmark
Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati
Aviano, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
Roma, Italy
I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione
Roma, Italy
Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
Rozzano, Italy
Nagoya University Hospital
Nagoya, Japan
National Cancer Center Hospital East
Kashiwa, Japan
Kindai University Hospital
Sakai, Japan
Shizuoka Cancer Center
Sunto, Japan
National Cancer Center Hospital
Chuo-ku, Japan
The Cancer Institute Hospital of JFCR
Koto-ku, Japan
Nederlands Kanker Instituut
Amsterdam, Netherlands
Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center
Groningen, Netherlands
Erasmus Medisch Centrum
Rotterdam, Netherlands
National University Hospital Medical Centre
Singapore, Singapore
National Cancer Center Singapore - Oncology Department
Singapore, Singapore
Icon Cancer Centre
Singapore, Singapore
Hospital Hm Nou Delfos | Oncologia
Barcelona, Spain
Hospital Universitari Vall D Hebron | Oncologia
Barcelona, Spain
Hospital San Pedro | Oncologia
Logroño, Spain
Hospital Universitario Fundacion Jimenez Diaz | Oncologia
Madrid, Spain
NEXT - Hospital Universitario Quironsalud Madrid | Oncologia
Pozuelo de Alarcón, Spain
Hospital Universitario Virgen De La Victoria | Oncologia
Málaga, Spain
Hospital Clinico Universitario De Valencia | Oncologia
Valencia, Spain
Clinica Universidad De Navarra | Pamplona | Oncologia
Pamplona, Spain
Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC
Stockholm, Sweden
Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH
Gothenburg, Sweden
The Christie Hospital | Experimental Cancer Medicine Team
Manchester, United Kingdom
The Royal Marsden Hospital (Sutton, Surrey) | Oak Foundation Drug Development Unit
Sutton, United Kingdom
Trial contact
Bayer Clinical Trials Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.